8-K current report · filed Nov 4, 2026

Niagen Bioscience, Inc. (NAGE) 8-K Current Report: November 4, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2NAGE overview

Short answer

Niagen Bioscience, Inc. (NAGE) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 fiscal 2026 earnings announcement for quarter ended September 30, 2026.

Niagen Bioscience, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 fiscal 2026 earnings announcement for quarter ended September 30, 2026
  • Exhibit 99.1 contains Niagen Bioscience’s detailed financial results and management commentary

Item 7.01 · Regulation FD Disclosure

  • Corporate presentation released November 4, 2026, providing updated company information to investors
  • Exhibit 99.2 contains the presentation, including potentially material business and strategic updates

Item EX-99.1 · Exhibit EX-99.1

  • Q3 net sales $27.2M, down from $34.0M; Tru Niagen contributed $23.3M
  • Gross margin 62.9%, while net loss reached $1.2M versus $4.6M net income last year
  • Adjusted EBITDA remained positive at $0.5M, but declined from $6.4M in Q3 2025
  • Cash $69.5M and operating cash flow $2.6M supported continued investment without disclosed borrowing
  • Product expansion includes at-home injections, skincare, Walmart.com, and nearly 300 GNC and Sam’s Club locations

Item EX-99.2 · Exhibit EX-99.2

  • Q3 2026 earnings presentation: net sales $27.2M, down 20% year over year, with Tru Niagen sales $23.3M
  • Profitability weakened: gross margin 62.9% versus 64.5%, net loss $(1.2)M, and Adjusted EBITDA $0.5M versus $6.4M
  • Core direct-to-consumer sales grew 13% year over year, while 2026 guidance targets 15-20% direct website growth
  • Liquidity remained strong: $69.5M cash, no borrowings, and $2.6M operating cash flow
  • Growth investment expanded through Niagen Plus injections, NanoCloud skincare, Walmart and GNC launches, and NB4168 development

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Niagen Bioscience, Inc. 8-K filings

Get the next NAGE 8-K as it lands

Follow NAGE for push alerts, or ask the research agent what this filing means.